Atea Pharmaceuticals (AVIR) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing novel orally administered antivirals for serious viral diseases.

• Lead program is a combination of bemnifosbuvir (nucleotide analog polymerase inhibitor) and ruzasvir (NS5A inhibitor) for hepatitis C virus (HCV).

• Aims to offer a differentiated, pan-genotypic, protease inhibitor-free regimen for HCV patients, including those with or without cirrhosis.

• Bemnifosbuvir is derived from a proprietary nucleotide platform, and ruzasvir is exclusively licensed from MSD International GmbH.

Financial performance and metrics

• As of September 30, 2024, 84,463,059 shares of common stock were outstanding.

• Up to $200 million in common stock may be issued in this offering, potentially increasing outstanding shares to 143,986,868, assuming full utilization at $3.36 per share.

• Additional shares are reserved for stock options, restricted stock units, and employee plans.

Use of proceeds and capital allocation

• Net proceeds will be used for research and development, preclinical and clinical activities, potential commercialization, working capital, and general corporate purposes.

• May also use proceeds to in-license, acquire, or invest in additional products, candidates, businesses, or technologies.

• Pending use, proceeds will be invested in marketable securities.